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1. Introduction 
1.1 Challenges of conventional drug delivery 
Traditional drug delivery systems include oral drug administration, injection, infusion, and 
topical administration, where the drug is applied to body surfaces such as the skin or 
mucous membranes. Many of the conventional drug delivery systems distribute the 
pharmaceutical compound proportionally to the regional blood flow through the systemic 
blood circulation. Consequently, the drug is delivered indiscriminately throughout the 
whole body to diseased and healthy tissues. As a result, patients suffer from side effects due 
to the non-specific delivery of the drug. Systemic delivery of a drug with body-wide 
distribution also results in a limited availability of the therapeutic agent at the site of 
interest, lowering the ability of the drug to produce a beneficial effect. To compensate for the 
low availability of the drug at the affected site, the drug has to be administered in large 
quantities, resulting in increased drug toxicity as well as high therapy costs. Another 
drawback of systemic drug delivery is the short circulation half-life of many drugs, which 
leads to the administration of high drug concentrations or high dosing frequencies (Branco 
& Schneider, 2009).  
Pain and discomfort caused by frequent drug applications are another challenge of 
conventional drug delivery, especially for children and the elderly. First steps have been 
made in the development of micro needle injection and needle-free injection to reduce the 
pain and inconvenience of injections (Brunner, 2004; Stoeber & Liepmann, 2002). As 
beneficial as mechanical improvements in drug delivery will be for the patient’s comfort and 
compliance, they will not reduce the number of administrations or the amount of required 
therapeutic. They also will not affect drug toxicity or effectiveness. To maximize the 
therapeutic effect of a drug, the appropriate concentration of the drug has to be available at 
the right location and time, while sparing healthy tissues. Therefore, new tools are needed 
that enable the delivery of drugs directly to the diseased area, and/or release the therapeutic 
agent in a controlled way.  
In this chapter, vehicles for the targeted delivery of drugs will be discussed, with special 
focus on the potential use of human mesenchymal stem cells (hMSCs) for targeted therapies. 
Besides the development of targeted drug delivery tools, efforts in the medical field attempt 
to increase the efficiency of conventional applications. An example is topical drug delivery, 
which has profited from the introduction of new topical applications including transdermal 
patches (Brunner, 2004), use of microneedles (Henry et al., 1998), electroporation techniques 
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(Escobar-Chavez et al., 2009), and the development of pulmonary delivery methods 
(Brunner, 2004). Additional methods to improve conventional drugs include sustained and 
controlled release technologies and enhanced absorption technology to provide more 
efficient drug absorption and increased bioavailability, as well as reduce pain from 
administration and improve ease of use (Brunner, 2004). These topics will not be further 
addressed in this chapter.  
1.2 Advantages of targeted drug delivery 
The ultimate goal of drug delivery is the efficient and timely transport of a drug to a diseased 
tissue, within the therapeutic and outside the toxic range, while sparing any healthy tissue. To 
progress towards this end, controlled drug delivery systems are being developed that can 1) 
control the rate of drug release, 2) control the location of drug release (spatial/targeted 
delivery), 3) or achieve both, temporal and spatial control of drug delivery (Hilt, 2010). 
Controlled delivery systems require the ability to localize and target drug action, extend drug 
action at a predetermined rate, and provide a physiologically/therapeutically based drug 
release system, which controls the rate of drug release based on the physiological/therapeutic 
needs of the body (Ding et al., 2006).  
Targeted drug delivery seeks to concentrate the medication in the tissues of interest while 
reducing the relative concentration of the medication in the remaining tissues. As a result, a 
high local drug concentration and low systemic exposure is achieved which helps to 
improve the drug’s effectiveness while lowering its damaging effects on healthy tissue. 
Especially in cancer therapy requiring highly toxic drugs, there is a great need for vehicles 
that transport drugs in a safe manner, very specifically to the diseased sites.  
Targeted drug delivery can rely on passive or active mechanisms. Passive targeting is 
mediated by the enhanced permeability and retention (EPR) effect, which is based on the 
longevity of the pharmaceutical carrier in the blood and its accumulation in pathological 
sites with compromised vasculature (Haley & Frenkel, 2008; Ruoslahti et al., 2010). Delivery 
tools relying on passive targeting mechanisms have limited target specificity, as passive 
targeting depends on the EPR effect, and thus on the degree of vascularization and 
angiogenesis of the targeted site. In cancer therapy, passive targeting makes extravasation of 
nanocarriers dependent on tumor type and tumor location. Active targeting, in contrast, is 
based on the attachment of specific ligands to the surface of pharmaceutical carriers to 
recognize and bind pathological target cells. The targeting ligands can be monoclonal 
antibodies, antibody fragments or non-antibody ligands, some of which will be discussed in 
the review. Despite the discrimination of active and passive mechanisms, it is important to 
keep in mind that active targeting cannot be separated from the passive because it occurs 
only after passive accumulation in the targeted site (Bae, 2009; Danhier et al., 2010).  
In summary, targeted drug delivery systems have several advantages over common 
systemic drug delivery methods (see Figure 1). The ability to convey the therapeutically 
active molecule only to the site of action, without affecting other organs and tissues, 
increases the therapeutic index, and allows for a lower required drug dose or dose 
frequency. This in turn increases the safety profile of the drug, and reduces side effects and 
risks, as less healthy tissue is targeted (Ruggiero et al., 2010). Equally important is the 
impact on the patient’s comfort, which will improve as a result of lower drug dose and side 
effects. Finally, the economic benefits of decreased drug use should be appreciated. The next 
section provides an overview of recent progress in the development of active and passive 
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systems for the targeted delivery of drugs, with a brief description of intracellular targeting 
strategies.  
 
                                Targeted Drug Delivery 
                                                              
                       
 High local drug dose                          Low systemic drug exposure 
                                                                
                                  
Lowered required dose                         Reduced drug side effects 
Lowered dose frequency                       
                                   
 
Improved drug safety profile                      Increased quality of life  
       Lower healthcare costs                                for patient
Fig. 1. Advantages of targeted delivery tools over conventional drug delivery methods 
2. Recent progress in the development of targeted drug delivery tools 
2.1 Nanoparticles 
Among other targeted drug delivery systems, nanoparticles have recently drawn strong 
interest in the medical community because of their utility as carriers. Nanoparticles come in 
a variety of sizes and shapes, like spheres, tubes, shells, and branched structures, and 
include among others, liposomes, quantum dots, nanospheres, nanocapsules, nanotubes, 
dentrimers, micelles, and fullerenes. One important aspect of nanoparticles is their limited 
size of up to 100nm (although the upper limit can vary in the literature), which enables them 
to pass through fenestrations of compromised leaky endothelium. As leaky epithelium is 
characteristic for tumors and their environment, nanoparticles can accumulate at tumor sites 
mediated by the EPR effect, and therefore can be used as a carrier for cancer therapeutics to 
the tumor (Danhier et al., 2010; Haley & Frenkel, 2008; Lowery et al., 2011). Besides being 
used in a passive drug delivery process, nanoparticles can be coupled to ligands which 
interact with their receptors at the target cell site and used in an active targeting process 
(Haley & Frenkel, 2008). Therapeutics can be encapsulated, entrapped, or attached to the 
nanoparticle surface and delivered to the tumor by the nanoparticles.  
The small size of nanoparticles also has a drawback. It results in the fast clearance of 
nanoparticles by the mononuclear phagocyte system (MPS), also called reticulo-endothelial 
system (RES), which is predominantly distributed in liver, lung, spleen, and bone marrow. 
Unless there is desired drug delivery to those organs, nanoparticles have to be surface 
modified with molecules like polyethylene glycol (PEG) to escape the MPS (Haley & 
Frenkel, 2008). PEG creates a steric barrier and prevents the interaction of nanoparticles with 
opsonins and phagocytic cells (Ishihara et al., 2009). Yang et al. (Yang et al., 2007) showed 
that the PEGylated liposomal formulation of paclitaxel significantly reduced the uptake by 
the MPS, while accumulation of liposomes at the tumor site, as well as biological half-life, 
were increased. Several drugs using nanoparticle carriers are already in preclinical and 
clinical use (Adiseshaiah et al., 2009; Bawa, 2008; Haley & Frenkel, 2008; Kim et al., 2010; 
Lowery et al., 2011; Ochekpe et al., 2009; Tuscano et al., 2010; Zhang et al., 2008), like 
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PEGylated doxorubicin (Doxil), and PEGylated daunorubicine (DaunoXome). Table 1 lists 
examples of approved nanoparticle-based therapeutics in clinical use.  
 
Brand Name Description Nanostructure Approved Indications 
Abelcet Amphotericin B 
lipid complex 
injection 
Liposomes  Invasive fungal infections in patients 
refractory or intolerant to amphotericin B 
Abraxane Albumin-bound 
nanoparticle 
formulation of 
Paclitaxel (Taxol) 
Protein 
nanoparticles 
 Breast cancer after failure of combination  
chemotherapy for metastatic disease or 
relapse within 6 months of adjuvant 
chemotherapy 
Adagen Pegademase 
bovine 
Polymeric 
nanoparticles 
 Adenosine deaminase deficiency in 
patients with severe combined 
immunodeficiency disease who failed or 
are not suitable candidates for bone 
marrow transplantation 
AmBisome Liposomal 
amphotericin B  
Liposomes  Systemic or disseminated infections due to 
Candida, Aspergillus, or Cryptococcus in 
patients who are refractory to or intolerant 
of conventional amphotericin B therapy, or 
have renal impairment 
 Visceral leishmaniasis 
Amphotec Amphotericin B 
lipid complex 
Lipid colloidal 
dispersion 
 Invasive aspergillosis in patients refractory, 
or intolerant to amphotericin B 
Copaxone Glatiramer acetate 
injection 
Polymeric 
nanoparticles 
 Relapsing-remitting multiple sclerosis, 
including patients who have experienced a 
first clinical episode and have MRI features 
consistent with multiple sclerosis 
DaunoXome Daunorubicin 
citrate liposome 
injection 
Liposomes  Advanced AIDS-related Kaposi's sarcoma 
Depocyt Cytarabine 
liposome injection 
Liposomes  Intrathecal treatment of lymphomatous 
meningitis 
Diprivan Propofol liposomes Liposomes  Induction and maintenance of anesthesia 
Doxil / 
Caelyx 
 
Doxorubicin HCl 
liposome injection 
Liposomes  Progressed or refractory ovarian cancer 
 AIDS-related Kaposi's sarcoma in patients 
with intolerance to, or failure of prior 
systemic chemotherapy 
 Myeloma in combination with bortezomib 
in patients who have not previously 
received bortezomib and have received at 
least one prior therapy 
Elestrin Estradiol gel 
incorporating 
calcium phosphate 
nanoparticles 
Calcium 
phosphate 
nanoparticles 
 Moderate-to-severe vasomotor symptoms 
(hot flashes) associated with menopause 
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Brand Name Description Nanostructure Approved Indications 
Epaxal* 
(Switzerland, 
Canada) 
Hepatitis A 
vaccine adjuvanted 
with 
immunopotentiati
ng reconstituted 
influenza 
virosomes 
Liposomes  Active immunization against hepatitis A  
Estrasorb Estradiol micellar 
nanoparticles 
Liposomes  Vasomotor symptoms in menopausal 
women 
Feridex Ferumoxides 
injectable solution 
Iron oxide 
Nanoparticles 
 Contrast agent for magnetic resonance 
imaging of liver lesions 
Macugen Pegylated anti-
VEGF aptamer 
Polymeric 
nanoparticles 
 Neovascular age-related macular 
degeneration 
Myocet*  
(Europe, 
Canada) 
Nonpegylated 
liposomal 
doxorubicin 
Liposomes  Metastatic breast cancer in combination 
with cyclophosphamide 
Oncaspar Pegaspargase Polymeric 
nanoparticles 
 First-line treatment of patients with acute 
lymphoblastic leukemia as a component of 
a multiagent chemotherapy regimen 
Neulasta Pegfilgrastim 
(PEG-rmetHuG-
CSF) 
Polymeric 
nanoparticles 
 Decrease incidence of infection manifested 
by febrile neutropenia in patients with non-
myeloid malignancies receiving 
myelosuppressive anti-cancer drugs 
associated with a clinically significant 
incidence of febrile neutropenia 
Pegasys Peginterferon alfa-
2a 
Polymeric 
nanoparticles 
 Chronic hepatitis C in patients coinfected 
with hepatitis C and HIV 
PEGIntron Peginterferon alfa-
2b 
Polymeric 
nanoparticles 
 Chronic hepatitis C infection with 
compensated liver disease 
Resovist Carboxydextran 
superparamagnetic 
iron oxide 
formulation 
Iron oxide 
nanoparticles 
 Contrast agent for magnetic resonance 
imaging of liver lesions 
Somavert Pegvisomant Polymeric 
nanoparticles 
 Acromegaly in patients with inadequate 
response to surgery and/or radiation 
therapy and/or other medical therapies, or 
for whom these therapies are not 
appropriate 
Triglide Nanocrystalline 
fenofibrate 
Nanocrystals  Primary hypercholesterolemia, mixed 
dyslipidemia, and hypertriglyceridemia, 
for use in conjuction with diet 
Verigene Gold nanoparticles Gold 
nanoparticles 
 In vitro diagnostics: genetic test for 
warfarin sensitivity 
* Not U.S. Food and Drug Administration (FDA) approved 
Table 1. Examples of approved nanoparticle-based therapeutics in clinical use 
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2.2 Ligand-targeted therapeutics 
Ligand-targeted therapeutics are based on the selective delivery of drugs to target cells by 
associating drugs with molecules that bind to antigens or receptors uniquely expressed or 
over-expressed on the target cell relative to normal cells (Allen, 2002). Such targeting ligands 
can be monoclonal antibodies, antibody fragments, and non-antibody ligands (Danhier et 
al., 2010). The drug of interest is directly conjugated to these targeting ligands, or loaded 
onto high capacity drug carriers, which are directly conjugated to targeting proteins or 
derivatized for interactions with specific adapters that are conjugated to the targeting 
protein (Backer et al., 2002). Ligand-targeted delivery systems rely on active targeting 
mechanisms, which help to improve target specificity, as the target ligands can act as 
“homing devices”,  improving the selective delivery of drug to specific tissue and cells 
(Danhier et al., 2010).  
Non-antibody targeting ligands include small molecules (folic acid, galactose), peptides 
(Arginine-Glycine-Aspartic acid (RGD), Vascular Endothelial Growth Factor (VEGF) 
peptide), aptamers (pegaptanib), and proteins, like transferrin and luteinizing hormone 
releasing hormone (Allen, 2002; Yu et al., 2010). Despite the advantage that non-antibody 
ligands are often readily available and inexpensive to manufacture, many of them bind 
relatively non-selectively to target and non-target tissue (Allen, 2002). For this reason, 
antibody ligands with higher cell selectivity, e.g. Anti-Human Epidermal Growth Factor 
Receptor 2 (HER2/neu/ERBB2), Anti-Vascular Endothelial Growth Factor Receptor 
(VEGFR), Anti-CD20, and Anti-CD33, have gained research attention (Allen, 2002; Park et 
al., 1997, 2002). However, the fact that antibody-targeted therapies rely on the expression of 
specific antigens is at the same time a drawback, as antigen expression is likely to change 
between patients, type of disease and time (Loebinger & Janes, 2010).  
To enable the delivery of highly potent cytotoxic agents to antigen-expressing cells, 
antibody-drug conjugates (ADCs) were designed, which take advantage of the site 
specificity of antibodies. The key components of an ADC are 1) the cytotoxic agent, 2) a 
monoclonal antibody targeting a tumor-enriched or tumor specific antigen, and 3) a linker 
that covalently binds these components together (Alley et al., 2010; Chari, 2008; Krop et al., 
2010). Unfortunately, the clinical success of ADCs so far has been very limited. Only 
gemtuzumab ozogamicin (Pfizer), an anti-CD33 monoclonal antibody linked to 
calicheamicin, had been approved by the FDA in the year 2000 for the treatment of patients 
with acute myeloid leukemia, but the product was voluntarily withdrawn from the US 
market in 2010 after results from a clinical trial raised concerns about the product’s safety 
and clinical benefit (Beck et al., 2010, 2011). Several ADC therapies are in clinical testing, 
including trastuzumab-DM1 (T-DM1) for breast cancer, brentuximab vedotin (SGN-35) for 
Hodgkin lymphoma (HL) and anaplastic large cell lymphoma (ALCL), and inotuzumab 
ozogamicin (CMC-544) for non-Hodgkin lymphoma (NHL) (Alley et al., 2010). T-DM1 is an 
antibody-drug conjugate which uses the HER2-binding antibody trastuzumab to deliver the 
potent antimicrotubule agent DM1 to HER2-expressing cells (Krop et al., 2010). A first 
clinical study with HER2-directed ADC in patients with HER2-positive metastatic breast 
cancer showed a clinical benefit rate (objective response plus stable disease at 6 months) of 
73% among 15 patients treated at the maximum tolerated-dose. The confirmed response rate 
among patients with measurable disease in this group was 44%. Based on those results, 
Burries et al. (Burris et al., 2011) evaluated T-DM1 treatment in patients with HER2-positive 
metastatic breast cancer who experienced progression on HER2-directed therapy in a single-
www.intechopen.com
 
Mesenchymal Stem Cells as Vehicles for Targeted Therapies 
 
495 
arm phase II study (study ID: TDM4258g). Among 112 treated patients, an objective 
response rate (ORR) of 26% was observed by independent assessment, which is comparable 
to the ORR of other HER2 therapies (Burris et al., 2011). The fact that response rates were 
higher among patients with confirmed HER2-positive tumors and among patients whose 
tumor HER2 expression levels were above the median, emphasizes the need for patient 
prescreening for HER2 target expression levels to obtain optimal results.  
Another ADC in advanced clinical development is SGN-35 (Seattle Genetics and 
Millennium Pharmaceuticals), comprised of an anti-CD30 monoclonal antibody linked to 
monomethyl auristatin E. CD30, is a defining marker of HL, but also expressed on other 
cancers, including ALCL. HL and ALCL patients were treated intravenously with SGN-35 
every 3 weeks for up to 16 cycles. With an objective response rate of 75% in HL and 86% in 
ALCL, SGN-35 represents the most active ADC reported. In February 2011, a biologics 
license application was submitted to the FDA (Beck et al., 2011; Deutsch et al., 2011). Many 
other ADCs are in early clinical trials and future results will reveal their benefit for clinical 
use. 
2.3 Cell penetrating peptides 
The transport of a therapeutic from the site of administration to the site of interest is not the 
only phase in drug delivery that can be controlled. After arrival of the drug at the site of a 
diseased tissue, it might also be necessary to control the transport of the drug across the 
plasma membrane of the targeted cells. Vehicles that facilitate and control intracellular 
transport are being developed and include physical delivery strategies, like electroporation, 
and biochemical delivery strategies, like cell-penetrating peptides (CPPs). CPPs are also 
named protein transduction domains and comprise short and usually basic amino acids-rich 
peptides originating from proteins able to cross biological barriers (Chou et al., 2011; Hassan & 
Elshafeey, 2010; Vives et al., 2008). They are able to act as vectors for the delivery of chemically 
conjugated biomolecules like peptides or oligonucleotides, and allow for viral-free 
transduction which eliminates the risk of virus vector induced complications. Besides the 
protein transduction domains (penetratin and TAT (48-60)), there are chimeric CPPs (MPG, 
transportan), synthetic CPPs (oligoarginine), and peptidic vectors designed from structure–
activity studies on already known CPPs (Pip2b, stearylated-Tp10). The mechanisms of 
internalization of CPPs are still controversial, and might be diverse, depending on CPP, cell 
type and cell cargo (Hassan & Elshafeey, 2010; Sawant & Torchilin, 2011).  
The most frequently used CPP is the TAT peptide (TATp), derived from the transcription 
activator protein encoded by human immunodeficiency virus type 1 (Torchilin, 2008). TATp 
can be covalently linked to many drug classes, including large protein molecules, and was 
used to transduce attached cargoes into cells of all organ types (Sawant & Torchilin, 2011). 
Responsible for the transduction ability of the TAT protein is the positive charge in the 
transduction domain which extends from residue 47 to 57. As for other CPPs, different 
mechanisms have also been proposed for the endocytic uptake of TATp, including classical 
clathrin-mediated endocytosis and clathrin-independent lipid raft-mediated caveolae 
endocytosis (Torchilin, 2008).  
Still, there are some challenges that must be overcome, like sequestration and entrapment of 
internalized material within endocytic vesicles, before CPPs can become a valuable clinical 
tool. Tools to enhance endosomal escape of CPP-attached cargos are developed and include 
the use of pH sensitive proteins, fusogenic lipids, membrane disruptive peptides, polymers, 
and lysomotropic agents. Another drawback is the lack of selectivity of certain CPPs, which 
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raises concerns about drug-induced toxicity in normal tissues (Chou et al., 2011; Sawant & 
Torchilin, 2011). The problem might be solved by combining target specific drug carriers 
with CPPs, to assure both delivery of the drug to the target cell and delivery of the drug 
from the outside of the cell into the cytoplasm of the target cell. 
2.4 Cells as delivery vehicles 
The ability of hematopoietic and non-hematopoietic cells to migrate to sites of injury, 
inflammation, and infection makes them attractive for investigation as a potential drug 
delivery vehicle. Cells can be loaded with drugs or modified to produce them, and then be 
used to carry the drug to the site of interest. The cell modifications can be done in many 
ways, including genetic cell engineering, and culture-induced modifications. 
Genetically-modified cells used in clinical trials are mainly autologous hematopoietic cells 
which are isolated from the patient, modified and reintroduced into the patient. Among 
hematopoietic cells, lymphocytes are the most commonly genetically modified cell 
population used in clinical trials, with lymphocytes expressing T-cell receptor (TCR) or 
Interleukin-12 (IL-12) for the treatment of advanced melanoma, and lymphocytes expressing 
Anti-P53 TCR, Anti-carcinoembryonic antigen (CEA), Anti-melanoma antigen family 
(MAGE)-A3/12 TCR, Anti-HER2, and Anti-NY ESO-1 (a cancer/testis antigen) TCR for the 
treatment of other metastatic cancers (see clinicaltrials.gov). The disadvantage of 
hematopoietic cells as delivery vehicle, and in transfusion medicine in general, is their 
immunogenicity. To avoid immune reactions of the patient’s immune system against the 
introduced cells, and attacks of the transplanted material against the recipient's body, 
autologous cells or AB0- and human leukocyte antigen (HLA)-matched cells must be used. 
An alternative to the use of hematopoietic cells are non-hematopoietic mesenchymal stem 
cells (MSCs), which are known for their low immunogenicity. The ability to use MSCs in an 
allogeneic setting eliminates the time consuming step of collecting stem cells from the 
patient and allows for the use of frozen, off-the-shelf cell products. The delay between 
diagnosis and availability of cells would be eliminated. In the following sections, MSCs in 
general and their use as potential drug delivery vehicles are discussed. 
3. Mesenchymal Stem Cell biology 
The therapeutic potential of MSCs is linked to a broad spectrum of MSC biological activities 
such as anti-inflammatory, immunomodulative and tissue reparative activities via paracrine 
mechanisms. Besides those activities, MSCs have the unique ability to home to sites of 
inflammation/injury and tumors, which makes them useful for the delivery of therapeutics 
to these sites. Cells are an ideal vehicle for targeted drug delivery, since they can be loaded 
with therapeutic agents and have the ability to migrate to sites of disease. This section 
describes current understanding of MSCs, their characteristics and biological activities, and 
current experience with MSCs in clinical trials that supports their use for targeted drug 
delivery. 
3.1 Background on MSCs 
The ability to generate an embryo from a single fertilized oocyte or to regenerate tissues 
upon injury or natural physiological turnover is a direct result of stem cells. As the embryo 
first develops, an undifferentiated mass of totipotent embryonic stem cells (ESCs) will form 
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a multicellular organism. As development proceeds, totipotent ESCs disappear as more 
restricted somatic stem cells (SSCs) give rise to the tissues and organs. Although cell 
diversification is mostly completed at or shortly after birth, organs must have a mechanism 
to replenish cells as they die as a result of natural homeostasis or injury. Therefore, after 
birth life-long reservoirs of SSCs are present in the body. Major characteristics of stem cells 
that distinguish them from all other cells include (1) self-renewal, or the ability to generate 
at least one daughter cell with characteristics similar to the initiating cell; (2) multi-lineage 
differentiation potential of a single cell; and (3) in vivo functional reconstruction of a given 
tissue. Adult SSCs fulfill these criteria, however the degree of self-renewal and 
differentiation potential are restricted in comparison to ESCs. There are several types of 
SSCs in the body including MSCs.  
MSCs were described as precursors of fibroblasts, which were isolated from bone marrow 
by Friedenstein in 1970 (Friedenstein et al., 1970). Upon culture at low density either as 
whole bone marrow or after cell separation over a density gradient, the cultured cells form 
characteristic colonies derived from a single precursor, referred to as colony forming unit 
fibroblasts or CFU-F. After ectopic transplantation under the kidney capsule, these cells 
gave rise to a broad spectrum of differentiated connective tissues including bone, cartilage, 
adipose and myelosupportive stroma (Owen, 1988; Prockop, 1997). Based on these 
observations it was proposed that these mesenchymal origin tissues are derived from a 
common precursor cell residing in bone marrow, termed the mesenchymal stem cell. These 
observations also led to the development and wide use of the colony forming unit-
fibroblasts (CFU-F) assay used to estimate MSC frequency among bone marrow nucleated 
cells. Using this technique, MSCs have been identified as a rare population of cells in bone 
marrow, representing ~0.001-0.01% of the nucleated cells (Pittenger & Martin, 2004). 
Estimation of MSC frequency in bone marrow using CFU-F shows that MSC number 
declines with age (Caplan, 2007), which correlates with poor mesenchymal tissue healing. 
This poor capacity for healing is evident, for example, in broken bones in elderly 
individuals. 
Adult, tissue specific stem cells are found in specialized niches in their corresponding 
tissues of origin. For example, hematopoietic stem cells (HSCs) can be found in bone 
marrow and epidermal stem cells are located in mammalian hair follicles. In contrast, cell 
types originated from MSCs are present through the entire body, and it has been shown that 
MSCs can be isolated from virtually all organs. There are three hypotheses regarding the 
location of MSCs in the body. In the first, MSCs are located in only one specific organ or 
tissue, from which they can migrate to other sites via the blood circulation to replenish the 
cell population. However, the number of MSCs circulating in blood is extremely low or 
undetectable. The difficulty establishing MSC culture from peripheral blood votes against 
this possibility. The second possibility is that MSCs are present in different tissues: MSCs 
have been successfully isolated from various tissues in addition to bone marrow. These 
tissues include adipose, periosteum, tendon, muscle, synovial membrane, skin and many 
others. When cultured in vitro, MSCs derived from different tissues show very similar 
characteristics and functionality, suggesting that different tissue-intrinsic stem cells might 
behave as MSCs when characterized in vitro. And the third possibility is that the MSC niche 
in vivo is the perivascular zone of blood vessels, and pericytes have all characteristics of 
MSCs. In this scenario, MSCs can actively participate in tissue repair after the release from 
blood vessels upon the damage in any tissue. Several experimental data support this 
hypothesis (da Silva Meirelles et al., 2008). 
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3.2 MSC immune privilege 
One of the most significant advantages of MSCs is that they can be used allogeneically. In 
vivo studies have demonstrated that tissues of mesodermal origin including bone, cartilage, 
and connective tissues, derived from MSCs, can be successfully transplanted without 
matching with a low incidence of acute rejection (Bacsich & Wyburn, 1947; Girdler, 1997). 
Thus, the mesodermal origin of MSCs suggests they are not recognized as foreign by the 
recipient immune system. Data accumulated in vitro and in vivo support the concept of 
MSCs as universally tolerated stem cells, rationalizing the transplantation of allogeneic 
MSCs without donor-recipient HLA matching. The universality is based on the low 
immunogenicity profile of MSCs. In vitro characterization has shown that MSCs 
constitutively express low levels of HLA class I molecules and do not express HLA class II 
molecules on the cell surface and co-stimulatory molecules like CD40, 80 and 86, which are 
essential for initiation of the immune response (Klyushnenkova et al., 2005; Tse et al., 2003). 
The absence of co-stimulatory molecules may lead to tolerance induction instead of rejection 
of allogeneic MSCs. The absence of host immune response against allogeneic MSCs has been 
demonstrated in vitro (Bartholomew et al., 2002; Di Nicola et al., 2002; Tse et al., 2003) and in 
vivo in animals (Atoui et al., 2008; Chen et al., 2009) and humans (Kebriaei et al., 2009; Le 
Blanc et al., 2004; Prasad et al., 2011; Sundin et al., 2007). 
3.3 MSC biological activities  
3.3.1 Regulation of hematopoiesis (stromal support) 
The critical role of bone marrow stroma for homing and long-term maintenance of 
hematopoiesis in mammalian bone was demonstrated early on by Friedenstein (Friedenstein 
et al., 1974). MSCs secrete a variety of cytokines, chemokines, and growth factors supporting 
hematopoietic cell expansion and maturation (Caplan, 2007; Deans & Moseley, 2000). Stromal 
Derived Factor-1 (SDF-1), which is produced by bone marrow stromal cells and mediates HSC 
homing and engraftment to the bone marrow, is one example of such chemokines. MSCs also 
play a critical role in megakaryocyte development: MSCs express thrombopoetin (TPO), IL-6, 
IL-11, Leukemia inhibitory factor (LIF) and Stem Cell Factor (SCF), which are critical 
regulators of megakaryopoiesis (Cheng et al., 2000). In addition to the regulation of 
megakaryopoiesis, MSCs also support cells of myeloid and lymphoid lineages. The ability of 
MSCs to support hematopoiesis was used in patients with hematopoietic cell graft failures. Co-
administration of MSCs together with hematopoietic stem cells enhanced engraftment and 
accelerated neutrophil, platelet, and lymphoid cell recovery (Ball et al., 2007; Fouillard et al., 
2003, 2007; Koc et al., 2000; Lazarus et al., 2005; Le Blanc et al., 2007). However, administration 
of MSCs together with hematopoietic cells resulted in high chimerism for hematopoietic cells 
in both blood and bone marrow, and microchimerism for MSCs – the majority of MSCs 
remained of host origin (Bacher et al., 2010; Bartsch et al., 2009). The low number of engrafted 
donor MSCs in bone marrow suggests that the support of hematopoietic cell engraftment and 
recovery is unlikely to be due to a stromal support function of donor MSCs. This MSC effect 
can be mediated rather by the MSC’s ability to modulate immune response, and thus, to 
prevent the hematopoietic graft rejection.  
3.3.2 Tissue protection and repair 
Accumulated data in animal models indicate that MSCs have the potential to protect and 
repair tissues in the body by several different mechanisms. First, mesenchymal tissue repair 
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can occur via MSC differentiation into cells of mesenchymal tissues. Since MSCs can be 
differentiated into distinctive mesenchymal phenotypes, they have been used for 
mesenchymal tissue regeneration by implanting MSCs in vivo into different tissue sites in 
tissue specific scaffolds. For example, MSCs can be delivered to bone or cartilage repair sites 
in calcium phosphate porous ceramics or hyaluronan and polymeric scaffolds for bone and 
cartilage repair, respectively (Bruder et al., 1998; Kon et al., 2000; Murphy et al., 2003; 
Solchaga et al., 2005). This approach resulted in well integrated, newly differentiated tissues 
(Kadiyala et al., 1997; Kon et al., 2000; Murphy et al., 2003), and showed that MSC-based 
tissue engineering is feasible for clinical use. MSCs have also been shown potential to trans-
differentiate into mature cells of non-mesenchymal origin. Reported data indicate that MSCs 
can be transdifferentiated into hepatocytes (Ong et al., 2006; Sato et al.; 2005), islet beta cells 
(Moriscot et al., 2005; Sun et al., 2007), endothelial cells (Oswald et al., 2004) and neural 
(Phinney & Isakova, 2005) or kidney tissues (Yokoo et al., 2005). These data show plasticity 
of MSCs and point to the possible use of MSCs for regenerative medicine of non-
mesenchymal tissues. In addition to the differentiation mechanism, the paracrine 
mechanism plays an important role in MSC-mediated tissue protection and repair. A set of 
MSC-derived factors with proangiogenic/proarteriogenic activities is shown by Kinnaird et 
al. (Kinnaird et al., 2004). Under hypoxic conditions MSCs promote proliferation and 
migration of endothelial and smooth muscle cells via secretion of VEGF and basic Fibroblast 
Growth Factor (bFGF), augmenting collateral remodeling that is critical for recovery from 
tissue ischemia. The effects of MSC-secreted biological active molecules can be direct, 
indirect, or both: direct by triggering intracellular signaling, or indirect by triggering 
another cell in the vicinity to secrete other biologically active factors. This indirect effect has 
been termed a “trophic” effect (Caplan & Dennis, 2006). In a variety of animal models, 
including myocardial infarction and stroke, MSC-mediated trophic effects are the primary 
mechanism involved in tissue repair (Caplan & Dennis, 2006). 
3.3.3 MSC-mediated immunomodulation 
An important function of MSCs is their role as potent immunomodulators. It was first 
observed by Osiris scientists, as well as others, that MSCs can inhibit T-cell proliferation 
both in vitro and in vivo (Bartholomew et al., 2002; Di Nicola et al., 2002). Subsequently, 
further studies have demonstrated that MSCs are able to regulate the immune system 
through cells of both the innate (macrophages, dendritic and natural killer cells) and 
adaptive (T- and B-cells) immune systems (Newman et al., 2009). A simplified schematic 
representation of MSC effects on different subsets of immune cells reflecting our current 
knowledge is captured in Figure 2. The ability of MSCs to inhibit immune response and 
down regulate secretion of inflammatory cytokines suggests that MSCs have the potential to 
treat inflammatory immune-mediated diseases such as graft versus host disease (GvHD), 
organ rejection, and autoimmune diseases. However, MSCs are not constitutively 
immunosuppressive. In a non-inflammatory environment, MSCs express low levels of COX-
2 (cyclooxygenase 2), Prostaglandin E2 (PGE2), Transforming growth factor ┚ (TGF-┚), 
Indoleamine 2,3-dioxygenase (IDO), and other factors that can inhibit immune response, 
however, pro-inflammatory cytokines such as Interferon ┛ (IFN-┛) and Tumor Necrosis 
Factor-┙ (TNF-┙) dramatically up-regulate the secretion of anti-inflammatory factors by 
MSCs (Aggarwal & Pittenger, 2005; English et al., 2007; Krampera et al., 2006; Meisel et al., 
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2004; Ryan et al., 2007). These in vitro data support a hypothesis of dynamic MSC response 
to inflammatory stimuli released from activated immune cells. In vivo animal data further 
demonstrate that MSCs require an ongoing immune response to exert their 
immunosuppressive functions (Renner et al., 2009). The dynamic response to cells and 
factors present in the microenvironment is an important feature and benefit of MSCs. Such 
regulated immunosuppressive activity of MSCs will help to avoid treatment-related 
complications that are common for traditional immunosuppressive drugs, particularly high 
rate of infections and multiple organ toxicities. 
The MSCs’ ability to regulate hematopoiesis, protect and repair tissues, and regulate 
immune reactions equips the cells with a great therapeutic potential. The therapeutic effects 
are well documented in animal models and are investigated in ongoing clinical trials 
(Parekkadan & Milwid, 2010). Whether those biological activities still play a role after MSCs 
modification for the transport of therapeutic drugs has to be determined. Especially for the 
treatment of inflammatory diseases it could be beneficial to combine the 
immunomodulatory effect of the MSCs with the therapeutic effect of MSC-delivered drug. 
Also, tissue repair activities would be beneficial in combination with therapeutic drugs, 
when injured tissue is targeted.  
3.4 MSC biodistribution and migration ability 
3.4.1 MSC biodistribution 
Understanding the biodistribution of MSCs in the body in its healthy, or baseline state is 
important for the development of MSCs as targeted drugs. For this reason, MSC 
biodistribution after infusion was studied in healthy animals (Allers et al., 2004). Allers et al. 
infused human bone marrow-derived technetium-99m (99mTc)-labeled MSCs intravenously 
into unconditioned mice. Fifteen minutes after infusion, radioactivity was detected in lungs 
and heart, suggesting blood vessel circulation of the infused labeled cells. Three hours later, 
MSCs were scattered in the body, but still accumulated in the lungs and also in the liver. 
The MSCs became temporarily entrapped in the lungs, probably as a consequence of 
significant differences in the diameter of MSC and inner lung capillary lumen. Whole-body 
scanning 24 hours after infusion revealed no or scarce radioactivity in the body, except for 
lungs, liver, and spleen. A similar pattern of short-term distribution of MSCs was observed 
in rats after syngeneic transplantation of indium-111-oxine–labeled rat MSCs (Gao et al., 
2001). After intraarterial (IA) and intravenous (IV) infusion, radioactivity associated with 
MSCs was first detected in the lungs and secondarily in the liver and other organs. Forty-
eight hours later, the radioactivity was observed primarily in the liver with considerable 
amounts detected in the lungs and kidneys (Gao et al., 2001). The long-term fate of 
systemically infused autologous and allogeneic MSCs was studied in non-human primates 
(Devine et al., 2003). Following lethal total body irradiation, which causes major damage to 
the bone marrow, baboons received green fluorescent protein (GFP)-labeled baboon MSCs 
by IV infusion. Tissue collection after 9 to 21 months after infusions showed that allogeneic 
and autologous MSCs appeared to distribute in a similar manner. The highest 
concentrations of engrafted cells per microgram of deoxyribonucleic acid (DNA) were found 
in gastrointestinal tissues including colon, duodenum, jejunum, and ileum. Kidney, lung, 
liver, thymus, and skin also harbored high amounts of DNA equivalents. Estimated levels of 
engraftment ranged from 0.1% to 2.7%. The data show that MSCs not only migrate to certain 
tissues, but can also engraft in low numbers at those sites. 
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Fig. 2. MSC effects on different types of immune cells. MSCs have both immunostimulative 
and suppressive activity, which is driven by type of immune cells and presence of cellular 
and molecular signals in local tissue microenvironment. Abbreviations: B = B-cells; CD = 
cluster of differentiation, molecules expressed on cell surface; DC1 and DC2 = dendritic cells 
types 1 and 2; IFN-┛ = interferon gamma; Ig = immunoglobulin; IL-4, 10, 12, 17 and 22 = 
interleukin 4, 10, 12, 17, and 22; MHC1 = major histocompatibility complex class I; MSC = 
mesenchymal stem cell; NK = natural killer cells; Th1, 2, and 17 = T helper cells 1, 2, and 17; 
TNF-┙ = tumor necrosis factor alpha; Treg = regulatory T-cells. Red arrows - 
decrease/inhibition. Green arrows - increase/stimulation. Black stealth arrows - stimulation 
of immune cells; black lines with blunt ends- suppression of immune cells 
3.4.2 Migration of MSCs towards injured tissue 
MSCs reside in various tissues including bone marrow, adipose tissues, amniotic 
membrane, and the umbilical cord (Motaln et al., 2010). In case of tissue damage, MSCs can 
be mobilized by signals such as cytokines and chemokines released from the damaged tissue 
and migrate to the sites of injury to participate in wound repair and tissue regeneration 
(Ramirez et al., 2006). Animal studies demonstrated that MSCs migrate to injured sites in the 
body, including the heart (Assis et al., 2010; Detante et al., 2009; Kraitchman et al., 2005; Wu 
et al., 2003), kidney (Herrera et al., 2007; Morigi et al., 2004), skin (Li et al., 2006), and bone 
(Horwitz et al., 1999; Mackenzie & Flake, 2001; Mosca et al., 2000). In rats bearing Lewis 
cardiac allografts, Wu et al. (Wu et al., 2003) found that IV injected ┚-galactosidase (lacZ) 
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labeled MSCs can migrate into lesions of chronic rejection in the cardiac grafts and home to 
the bone marrow. In a myocardial infarction model in rats, Assis et al. (Assis et al., 2010) 
showed that systemically delivered 99mTc -labeled hexamethylpropyleneamine oxime (99mTc-
HMPAO) and 4',6-diamidino-2-phenylindole (DAPI)-labeled MSCs migrate to the infarcted 
area. One hour after MSC injection, the radioactivity in infarcted hearts was 23-fold higher 
than in control hearts, and a week later DAPI-labeled MSCs were still detected in the 
infarcted areas of the heart (Assis et al., 2010). In a similar study, 99mTc-hMSCs were injected 
into the saphenous vein of rats one week after cerebral ischemia (Detante et al., 2009). After 
initial entrapment of the cells in the lungs, they were able to migrate towards the ischemic 
brain lesion. Finally, the MSCs were sequestered in the spleen and eliminated 
predominantly by the kidneys. MSC migration was also studied in mice with induced renal 
injury. After IV injection of MSCs into syngeneic female mice one day after induction of 
kidney injuries, MSCs were detected in the context of the well-differentiated tubular 
epithelial lining. MSCs strongly protected renal function as reflected by significantly lower 
blood urea nitrogen values (Morigi et al., 2004). In a canine model, MSCs were also shown to 
migrate to the bone marrow after myeloablation of dogs via total body irradiation (Mosca et 
al., 2000). After MSC transfusion, 58% of the bone marrow samples analyzed were transgene 
positive. Engrafted MSCs were viable at least 6 months after infusion. The animal studies 
clearly show the MSCs’ ability to migrate to sites of injury to participate in tissue repair 
processes and demonstrate their potential as vehicles for gene delivery.  
The migration ability of MSCs was also studied in human patients with osteogenesis 
imperfecta (Horwitz et al., 2002). Osteogenesis imperfecta is a genetic disorder of 
mesenchymal cells in which generalized osteopenia leads to bony deformities, excessive 
fragility with fracturing, and short stature mostly due to a mutation in one of the two genes 
encoding type I collagen. Intravenous infusions of allogeneic, gene-marked, marrow-
derived MSCs in patients with osteogenesis imperfecta resulted in the migration of the cells 
to the bone, skin, and marrow stroma, and their engraftment in one or more of these sites 
(Horwitz et al., 2002).  
3.4.3 MSC migration to cancer tissue  
MSCs do not only show tropism to sites of injury, but also to sites of tumorigenesis. In both 
cases, inflammatory mediators are involved in recruitment of MSCs. Factors involved include 
cytokines and growth factors like Epidermal Growth factor (EGF), Hepatocyte Growth Factor 
(HGF), Insulin like Growth Factor 1(IGF-1), IL-1-┚, IL-8, Platelet Derived Growth Factor 
(PDGF), SDF-1, TGF-┚, TNF-┙, and VEGF (Birnbaum et al., 2007; Forte et al., 2006; Ji et al., 
2004; Klopp et al., 2007; Motaln et al., 2010; Nakamizo et al., 2005; Ponte et al., 2007; Ries et al., 
2007; Xu et al., 2010). Many of the same inflammatory mediators secreted by wounds are also 
found in tumor microenvironment and thought to be involved in attracting MSCs to these sites 
(Spaeth et al., 2008). Dvorak actually described the tumor as an unhealed wound that produces 
a continuous source of inflammatory mediators (Dvorak, 1986). Inflammation is a component 
present during all steps of tumor development and in all types of tumors (Sansone & 
Bromberg, 2011; Spaeth et al., 2008; von Hertzen et al., 2011; Wallace et al., 2010).  
The migration of MSCs to tumors is well documented (Loebinger et al., 2009a, 2009b; 
Nakamizo et al., 2005; Studeny et al., 2002, 2004; Xin et al., 2007). Loebinger et al. studied 
MSC migration in metastatic xenograft cancer models (Loebinger et al., 2009a, 2009b). 
Metastatic lung tumors were produced by the delivery of MDA-MB-231 cells into the lateral 
tail vein of mice, and visualized as focal regions of increased signal with magnetic resonance 
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imaging (MRI). Thirty-five days after setup of the animal model, human MSCs double-
labeled with DiI and iron nanoparticles were injected into the lateral tail vein of the animals. 
MRI one hour after injection showed a decrease in signal intensity caused by the iron oxide 
in MSCs in areas of metastatic deposits detected in pre-MSC delivery images (Loebinger et 
al., 2009b). The in vivo experiments confirmed results from in vitro transwell migration 
studies, which had demonstrated tumor homing of iron nanoparticle–labeled and unlabeled 
MSCs. The migration potential of MSCs towards tumors could also be shown for murine 
osteosarcoma (Xu et al., 2009), murine fibrosarcoma (Xiang et al., 2009), and murine glioma 
models (Nakamizo et al., 2005). 
The number of MSCs that reaches a site of injury or tumorigenesis after systemic 
administration may not always be sufficient to have a therapeutic effect. In those cases, 
ways have to be found to enhance MSC migration. As radiation increases the expression of 
inflammatory mediators, it was argued that it might also enhance the recruitment of MSCs. 
Klopp et al. addressed the question by irradiation of murine breast carcinomas and showed 
that migration of MSCs to the tumor environment can indeed be enhanced by irradiation. 
Twenty-four hours after unilateral irradiation of 4T1 breast carcinomas, MSCs expressing 
firefly luciferase were injected intravenously into the animals. Forty-eight hours post 
irradiation, levels of MSC engraftment were 34% higher in tumors receiving 2 Gy (p = 0.004) 
than in the contralateral unirradiated limb. Immuohistochemistry also revealed higher 
levels of MSCs in the parenchyma of radiated tumors. Irradiated 4T1 cells resulted in 
increased expression of the cytokines, TGF-┚1, VEGF, and PDGF-BB, known to be involved 
in MSC migration (Klopp et al., 2007). Similar results were obtained in murine colon cancer 
xenograft models (Zielske et al., 2009). Thus, low dose irradiation might be a potential 
clinical tool to increase the tropism for and engraftment of MSCs in the tumor 
microenvironment. Another option to increase the in vivo migratory and adhesion capacity 
of MSCs is the activation of MSCs with proinflammatory cytokines like TNF-┙ prior to 
treatment (Dwyer et al., 2007; Spaeth et al., 2008). 
3.5 Safety of human MSCs in clinical trials 
The clinical use of MSCs started in the 1990’s (Horwitz et al., 1999; Koc et al., 2000; Lazarus 
et al., 1995). There were no adverse events linked to MSCs, and some clinical benefits were 
observed after MSC infusions. Today more than 100 clinical trials are registered at 
clinicaltrials.gov. These clinical trials are using bone marrow, adipose or placenta-derived 
MSCs and are covering a wide spectrum of diseases (see Table 2). More than half of the 
registered trials utilize autologous MSCs. The routes of delivery include both systemic and 
local administration.  
Osiris Therapeutics has experience with numerous clinical trials utilizing expanded human 
allogeneic MSCs (Prochymal® (remestemcel-L)), which allow for immediate treatment of 
patients with no delay due to cell processing that occurs with the use of autologous MSCs. 
Human MSCs have been used by Osiris for the treatment of immunologic, gastrointestinal, 
cardiac, and orthopedic indications. Prochymal® is being evaluated in Phase III clinical trials 
for several indications, such as acute GvHD and Crohn's disease. ChondrogenTM, an 
injectable formulation of MSCs, is under investigation for the treatment of arthritis in the 
knee. Altogether, more than 1,300 patients have been treated in Osiris clinical trials. With 
much of the data from double-blinded, placebo-controlled studies, the results provide 
strong support for the positive safety profile of MSCs. 
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MSC Type MSC Source Therapeutic Areas 
 Autologous 
 Allogeneic 
 Bone Marrow 
 Adipose 
 Placental-derived 
 Inflammatory and immune-mediated  
 Cardiovascular 
 Orthopedic 
 Gastrointestinal/Liver/Pancreatic 
 Neurological 
 Pulmonary 
 Nephrological 
 Dermatological 
 Hematological 
 Metabolic  
 Genetic  
Table 2. MSCs in clinical trials 
Valuable safety information has been obtained from these studies because of the diverse 
patient population, including adult and pediatric patients, and the wide range of dosing 
regimens studied in Osiris clinical trials. No infusional toxicities were observed in both 
adult and pediatric populations. Overall review of safety data, including adverse events, has 
detected no trends or signals in the events experienced by patients attributed to 
administration of MSCs (Hare et al., 2009; Kebriaei et al., 2009; Lazarus et al., 2005; Prasad et 
al., 2011). Consistent with Osiris’ data, the safe use of MSCs has also been reported by other 
investigators (e.g. Chen et al., 2004; Ciccocioppo et al., 2011; Duijvestein et al., 2010; Le Blanc 
et al., 2008; Lucchini et al., 2010; Williams et al., 2011). The safety of MSCs, together with the 
ability to use unmatched allogeneic MSCs and the potential of MSCs to home to the sites of 
inflammation or injury,  makes these cells a promising candidate for drug delivery vehicles. 
4. MSCs - A drug delivery tool 
The unique ability of MSCs to migrate to sites of inflammation, modulate immune and 
inhibit inflammatory responses, and prevent and repair tissue damage, make MSCs an 
attractive cell therapy for the treatment of diseases with inflammatory components 
(Newman et al., 2009). It is those features, as well as MSCs’ low immunogenicity profile 
allowing for allogeneic, off-the-shelf use, that makes MSCs promising as a cell therapy.  
Table 3 summarizes the important features of MSCs for use in drug delivery. 
 
 Characteristics supporting the use of MSCs as a vehicle for drug delivery 
 Selective MSCs homing to sites of inflammation and cancer 
 Low immunogenicity profile of MSCs which allows for allogeneic use of MSCs 
 Allogeneic use of MSCs enables development of “off-the-shelf” drugs 
 Established biodistribution and toxicology profile 
 Positive safety profile of MSCs in clinical trials to date 
 Easy availability of MSCs from adult bone marrow donors and other sources 
 Potential for GMP-compliant, large-scale manufacturing processes 
 Cryopreservation for long-term storage of MSC products 
Table 3. Features of MSCs for use as a drug delivery system 
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4.1 MSCs as vehicle for therapeutic drugs 
4.1.1 MSCs as vehicle for cancer therapeutics 
Recent data providing evidence that MSCs migrate to sites of tumorigenesis in some 
instances suggest another therapeutic area for MSCs: the use of MSCs as a vehicle for the 
targeted delivery of cytotoxic agents to tumor tissue (Hall et al., 2007; Hu et al., 2010). Cells, 
like MSCs, which are able to target cancer cells, and are, at the same time, non-immunogenic 
and non-toxic to the host are the ideal vehicle for tumor-selective drug delivery. Several 
preclinical studies support the rationale for genetically modified MSC to deliver 
therapeutics to tumor sites. Successful animal models include sarcoma, melanoma, 
carcinoma, and several cancer metastasis models. Table 4 gives an overview of preclinical 
studies focusing on the delivery of genetically modified MSCs for cancer therapy. 
 
 
Genes Delivered By MSCs Treated Tumor Reference 
Cytosine deaminase in combination with 5-
FC  
Colon cancer 
Melanoma 
(Kucerova et al., 2007) 
(Kucerova et al., 2008) 
CD : UPRT  Human prostate 
tumor 
(Cavarretta et al., 2010) 
CRAd 
 
 
Ovarian carcinoma  
Intracranial glioma 
Tumor metastasis 
(Komarova et al., 2006) 
(Sonabend et al., 2008) 
(Stoff-Khalili et al., 2007) 
CX3CL1 (Fractalkine) Tumor metastasis (Xin et al., 2007) 
EGFRvIII Glioma (Balyasnikova et al., 
2010) 
Interferon-┙ Tumor metastasis (Ren et al., 2008a) 
Interferon-┚ 
 
 
Glioma 
Tumor metastasis 
Tumor metastasis 
(Nakamizo et al., 2005) 
(Ren et al., 2008b) 
(Studeny et al., 2004) 
Interleukin-2 
 
Glioma 
Melanoma 
(Nakamura et al., 2004) 
(Stagg et al., 2004) 
Interleukin-12 
 
 
Tumor metastasis 
Ewing sarcoma 
tumors 
Melanoma 
(Chen et al., 2008) 
(Duan et al., 2009) 
(Elzaouk et al., 2006) 
iNOS Fibrosarcoma (Xiang et al., 2009) 
NK4 (adenovirus) Tumor metastasis (Kanehira et al., 2007) 
(Delta)24-RGD (adenovirus) Glioma  (Yong et al., 2009) 
TRAIL 
 
 
Tumor metastasis 
Glioma 
Carcinoma 
(Loebinger et al., 2009a) 
(Sasportas et al., 2009) 
(Mohr et al., 2008) 
Abbreviations: CD: UPRT = cytosine deaminase: uracil phosphoribosyltransferase; CRADs = 
conditionally replicating adenoviruses; EGFRvIII = mutant epidermal growth factor receptor; 5FC = 5-
fluorocytosine; iNOS = inducible nitric oxide synthase; TRAIL = tumor necrosis factor related 
apoptosis-inducing ligand 
Table 4. Preclinical studies of genetically engineered MSCs for the delivery of anti-cancer 
agents to tumors.  
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Among others, recent efforts focused on the delivery of anti-proliferative and pro-apoptotic 
therapeutics, like Interferon-┚ (IFN-┚) (Chawla-Sarkar et al., 2001; Johns et al., 1992). The 
therapeutic efficacy of IFN-┚ had been limited by its toxicity associated with systemic 
administration (Menon et al., 2009). To be able to minimize toxicity and increase the local 
concentration of IFN-┚, MSCs were selected as delivery vehicle. Murine MSCs were 
engineered to release IFN-┚ and injected via tail vein into immunocompetent mice with 
prostate cancer lung metastasis (Ren et al., 2008b). Following IFN-┚-expressing MSC 
therapy, the mice showed a reduction of tumor volume in the lung, increased tumor cell 
apoptosis, decreased tumor cell proliferation and blood vessel counts, and an increase in the 
natural killer cell activity. The systemic level of IFN-┚ was not significantly elevated by the 
targeted cell therapy (Ren et al., 2008b).  
MSCs expressing IFN-┚ were also used for targeted delivery of interferon to metastatic 
breast carcinoma and melanoma models (Studeny et al., 2004). To establish pulmonary 
metastases, mice were injected MDA-MB-231 tumor cells in the lateral tail vein. Eight days 
after tumor cell injection, mice started treatment with recombinant IFN-┚, IFN-┚-MSCs, or 
MSC-Gal by intravenous injection (Studeny et al., 2004). Whole lung weight was used as a 
surrogate endpoint of MDA-MB-231 tumor burden in the lung. Tumor mice treated 
intravenously with MSC-IFN-┚ cells had significantly smaller lungs then untreated control 
mice injected with tumor cells only (mean lung weight 0.408 g versus 0.977 g; p = 0.021). By 
contrast, there was no statistically significant difference in the mean lung weight of mice 
treated with recombinant IFN-┚ or MSC-Gal cells and control mice injected with tumor cells 
only. Intravenous administration of human IFN-┚-MSCs also prolonged the survival of 
animals with established metastases of MDA-MB-231 breast carcinoma (median survival 60 
days versus 37 days in control mice, p < 0.001) and A375SM melanoma tumor in the lung 
(median survival 73.5 days versus 30 days in control mice, p < 0.001) (Studeny et al., 2004).  
Another therapeutic with encouraging preclinical results in MSC-targeted cancer therapy is 
the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), a transmembrane 
protein, which induces apoptosis in various tumor cell types (Hao et al., 2001; Kagawa et al., 
2001). Loebinger and coauthors (Loebinger et al., 2009a) showed that directly delivered 
TRAIL-expressing MSCs were able to significantly reduce tumor growth (p < 0.001) in 
subcutaneous xenograft experiments. In a pulmonary metastasis model, systemically 
delivered TRAIL-expressing MSCs localized to lung metastasis, and the controlled local 
delivery of TRAIL completely cleared lung metastases in 38% of mice compared to none of 
the controls (p < 0.05) (Loebinger et al., 2009a). Anti-tumorigenic effects of MSC-delivered 
recombinant TRAIL were also reported from human glioma models (Sasportas et al., 2009). 
The ability of MSCs to target primary tumors and their metastases suggests an important 
therapeutic role for MSCs as drug delivery vehicles in the future. 
4.1.2 MSCs as vehicle for prodrug gene therapy 
A very promising approach to reduce cancer drug toxicity is prodrug gene therapy, based 
on the delivery of genes encoding enzymes that convert nontoxic prodrugs into toxic 
antimetabolites (Menon et al., 2009). One of the chemotherapeutic agents of interest for 
prodrug gene therapy is the prodrug 5-Fluorocytosine. This prodrug is converted to the 
potent chemotherapeutic substrate 5-fluorouracil by the bacterial and/or yeast cytosine 
deaminase enzyme. 5-Fluorouracil has been used successfully for colorectal and pancreatic 
cancer therapy for about 40 years. Despite the fact that it is a potent chemotherapeutic agent, 
its high toxicity results in severe side effects in treated patients. The development of a 
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prodrug, which is only converted into the toxic chemotherapeutic agent at the site of 
tumorigenesis, is an important step to achieve lower toxicity of 5-fluorouracil. Kucerova et 
al. combined MSC-driven targeted delivery of the prodrug converting enzyme cytosine 
deaminase: uracil phosphoribosyltransferase with the systemic administration of the 
prodrug 5-fluorocytosine (Kucerova et al., 2007, 2008). The administration of MSCs 
expressing the prodrug converting enzyme (CDy-AT-MSCs) in combination with systemic 
delivery of 5-Fluorocytosine, inhibited subcutaneous human colon cancer growth in 
immunocompromised mice. By day 18, significant inhibition of tumor growth of up to 69% 
was observed in all animals injected with CDy-AT-MSC. The animals did not show any 
signs of toxic side effects of the therapeutic regimen.  
Also in a murine melanoma model, systemic administration of CDy-AT-MSC resulted in cell 
homing into subcutaneous melanoma and mediated tumor growth inhibition (Kucerova et 
al., 2008). A similar study on pancreatic cancer was recently conducted by Cararetta et al. 
(Cavarretta et al., 2010). After induction of PC3 tumors in mice, the animals received 
systemic administration of CDy-AT-MSCs and were daily treated with 5-Fluorocytosine. On 
day 24, average tumor volume had decreased in all treated animals compared to control 
animals. In a second group with repeated CDy-AT-MSC injections, complete regression of 
the tumor was observed at day 36 in three out of six mice. The studies confirm that MSC 
have the potential to travel to site of tumorigenesis and to effectively deliver prodrug 
converting enzymes. Targeted delivery of prodrug-converting enzymes in combination with 
the systemic delivery of the according prodrug might substantially reduce side effects of 
otherwise highly toxic therapeutics. 
4.1.3 MSCs as vehicle for biological pacemaker genes 
In addition to the development of MSCs as delivery vehicles for cancer therapeutics, much 
research in MSC delivery tools focuses on the delivery of biological pacemakers for the 
treatment of heart diseases. Electronic pacemakers, the standard of care for heart block and 
other electrophysiological abnormalities, still have shortcomings, like limitations on exercise 
tolerance and cardiac rate-response to emotion; limited battery life, interference with neural 
stimulators, metal detectors, and MRI equipment; effects on electrophysiological or 
contractile function; and sizing challenges for growing pediatric patients (Rosen et al., 2004, 
2008). Biological pacemakers that would create a stable physiological rhythm, not require 
electronic equipment and adapt to changes in activity and emotion, would be an attractive 
alternative. MSCs might serve as a platform for the delivery of pacemaker genes. First proof 
of concept was collected in a canine study by Potapova et al. (Potapova et al., 2004). Human 
MSCs were engineered to express the biological pacemaker gene mHCN2 and administered 
into the left ventricular wall of adult dogs. The animals were subjected to a pericardiectomy 
and within ten days, vagal stimulation was performed to induce atrioventricular block and 
to analyze whether escape pacemaker function occurred. Five of six animals receiving 
hMSCs expressing the biological pacemaker and the enhanced green fluorescent protein 
(EGFP) reporter gene developed rhythms originating from the left ventricle and pace-
mapped to the injection site. Only two out of four control animals, which had received 
MSCs expressing EGFP alone, developed right ventricular escape rhythms. Dogs who had 
received the biological pacemaker gene developed idioventricular rhythms with rates 
approximating on average 61 beats per minute (bpm), while the rates of control animals 
only reached 45 bpm (p < 0.05; (Potapova et al., 2004)). Nests of adult human MSCs were 
found at the site of injection, as well as evidence for gap junctional coupling between adult 
MSCs and myocytes.  
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In another study from the same group (Plotnikov et al., 2007), mHCN2 expressing MSCs 
were administered into the left ventricular wall of adult dogs in complete heart block and 
with backup electronic pacemakers to operate in “tandem” mode. After stabilization around 
day 10 to 12, the biological pacemaker functioned stably and with little time-dependent 
variation in dogs that had received at least 700,000 hMSCs. The pacemaker function was 
stable until the end of the study at day 42. Following Plotnikov et al., no cellular or humoral 
rejection, loss of function, or apoptosis was observed during this time (Plotnikov et al., 
2007). A later analysis by Rosen et al. (Rosen et al., 2008) assessed the observation of loss of 
function and histological evidence of rejection in some of the xenotransplants. The studies 
show that, despite great progress in the development of MSCs as vehicles for biological 
pacemakers, some questions remain unanswered. Further studies are needed to investigate 
how reliable and durable pacemaker function can be obtained without rejection and how the 
cells can be maintained in the target area. 
4.1.4 Clinical progress with MSCs delivering therapeutics 
While many preclinical studies have shown proof of concept for the use of MSCs as targeted 
delivery vehicle, clinical studies are focused on unmodified human MSCs. Additional 
modification of the cells may help to increase levels of therapeutics generated by the cells, or 
induce the production of therapeutics which are not present in naïve cells. MSCs can be 
modified using genetic and non-genetic techniques, including the pre-differentiation of 
MSCs in growth factor containing media. In a first clinical study, adipose-derived insulin-
producing MSCs (h-AD-MSC) were used for the treatment of type 1 diabetes mellitus (DM), 
an autoimmune disorder with disturbed glucose/insulin metabolism, which has no medical 
treatment other than life-long insulin therapy (Trivedi et al., 2008). To obtain MSCs that 
produce insulin, the adipose-tissue derived MSCs were cultured in differentiation medium. 
The DM patients received intraportal administration of h-AD-MSC together with 
xenogeneic-free, cultured bone marrow-derived hematopoietic stem cell transplantation. 
Five insulinopenic DM patients at the age of 14 to 28 years received a mean dose of 3 million 
h-AD-MSC. The patients showed 30% to 50% decreased insulin requirements with 4- to 26-
fold increased serum c-peptide levels, at a mean follow-up of 2.9 months. No adverse side 
effects related to the stem cell infusion or the administration of induction therapy were 
reported. The study provided initial evidence of potential treatment of insulinopenic 
diabetics using insulin-producing h-AD-MSC in conjunction with hematopoietic stem cell 
transplants. It is a first step in the use of modified MSCs in clinical settings, and additional 
larger studies will be important to assess the durability of the response. 
Another clinical study with autologous cultured mesenchymal bone marrow stromal cells 
secreting neurotrophic factors (MSC-NTF, NurOwn™) is planned by the Hadassah Medical 
Organization in Jerusalem, Israel, in collaboration with Brainstorm Cell Therapeutics Ltd. 
The study will evaluate the safety and therapeutic effects of MSC-NTFs injections as a 
treatment for patients with amyotrophic lateral sclerosis (ALS). ALS, also called Lou 
Gehrig's disease, is a progressive neurodegenerative disease that affects nerve cells in the 
brain and the spinal cord, characterized by progressive degeneration of motor neurons. 
Animal studies have shown that glial-derived neurotrophic factor (GDNF) can protect 
motor neurons from degeneration in vitro (Henderson et al., 1994; Suzuki et al., 2007). For 
this clinical study, adult bone marrow cells capable of releasing neurotrophic factors, 
including GDNF, will be generated and transplanted into ALS patients. In early ALS 
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subjects, MSC-NTF cells will be transplanted intramuscularly, while cells will be 
administered intrathecally in progressive ALS patients. The hypothesis is that the 
administration of MSCs expressing GDNF might protect motor neurons from further 
neurodegeneration. Results are not available yet, as the study is in its early stages. 
4.2 MSCs as vehicle for nanoparticles 
Nanoparticles can be used not only as a carrier for drugs, but also as a diagnostic and 
therapeutic tool. As nanoparticles reach their target site by passive targeting via the EPR 
effect, their target specificity is limited. Target specificity, however, could be improved by 
using MSCs as a vehicle to deliver nanoparticles specifically to sites of inflammation and 
tumorigenesis. At the site of interest, the nanoparticles could serve different purposes, 
dependent on the nanoparticle material and therapeutic aim.  
An essential requirement for the development of nanoparticle-carrying MSCs as a diagnostic 
or therapeutic tool is the successful uptake of nanoparticles by the cells and low toxicity of 
the nanoparticles within the cell. Studies have shown that, among other factors, nanoparticle 
size, shape and surface charge play an important role in the uptake of nanoparticles in cells 
(Chithrani & Chan, 2007; Chithrani et al., 2006; Jo et al., 2010; Patra et al., 2010). Chithrani et 
al. investigated the intracellular uptake of different sized and shaped colloidal gold 
nanoparticles in HeLa cells and other mammalian cell lines (Chithrani & Chan, 2007; 
Chithrani et al., 2006). Gold nanoparticles were used as a model nanoparticle system, as 
their size and shape can be easily controlled during synthesis, and quantification of the 
nanoparticles is possible in biological samples. Among spherical nanoparticles with 
diameters between 14 nm and 100 nm, the maximum uptake by a cell occurred at a 
nanoparticle size of 50 nm. Similar findings were made by other research groups (Malugin 
& Ghandehari, 2010). The uptake of rod-shaped gold nanoparticles was lower, and the 
fraction of exocytosed rod-shaped nanoparticles higher, than that of their spherical 
counterpart. In general, exocytosis occurred at a higher rate and higher percentage in 
smaller compared to larger nanoparticles. Thus, both, uptake and removal of nanoparticles 
were highly dependent upon the size of the nanoparticles, but the trends were different 
(Chithrani & Chan, 2007). Besides nanoparticle size and form, the type of ligand coating the 
cells also influenced the cellular uptake. The number of transferrin-coated gold 
nanoparticles that entered the cells was about three times less than that of the citrate-
stabilized gold nanoparticles (Chithrani et al., 2006). The uptake of gold nanoparticles was 
also investigated in MSCs (Koshevoy et al., 2010; Yamada et al., 2009). In-depth knowledge 
of nanoparticle properties crucial for cellular uptake will help to accelerate the development 
of nanoparticle candidates for targeted cell therapies. 
4.2.1 Nanoparticle labeled cells as diagnostic tool 
The development of nanoparticle-loaded MSCs in the recent past has concentrated on 
diagnostic applications. The nanoparticles of choice for such cell labeling studies in MSCs 
were superparamagnetic iron oxide (SPIO) particles which can be used to track the 
biodistribution and migration of transplanted cells by MRI and other imaging methods 
(Arbab et al., 2004; Bulte et al., 2005; Chen et al., 2010a; Jo et al., 2010; Kostura et al., 2004; 
Loebinger et al., 2009b; Reddy et al., 2010; Walczak et al., 2005). Tracking labeled MSCs after 
transplantation will enable a better understanding of the dynamics of cell-tissue interactions 
and help improve the design of stem cell therapies by optimizing cell manufacturing and 
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cell delivery protocols (Bulte et al., 2005; Srinivas et al., 2010). The impact of nanoparticle 
uptake on cell viability and cell functionality was analyzed in in vitro studies. Bulte et al. 
injected poly-L-lysine coated ferumoxide (PLL-Feridex) labeled canine MSCs via MR 
fluoroscopy in a canine myocardial infarction model, and followed their biodistribution 
(Bulte et al., 2005). The cells could be serially tracked by MRI for at least eight weeks 
following implantation. Feridex-labeling did not affect cell proliferation, adipogenesis, or 
osteogenesis, but markedly diminished the cells’ ability to undergo chondrogenesis (Bulte et 
al., 2005; Kostura et al., 2004). This could also be shown for human MSCs labeled with SPIO 
nanoparticles coated with carboxydextran (Resovist) by Reddy et al. (Reddy et al., 2010), 
while Schäfer et al. (Schäfer et al., 2010) did not observe such effect. In contrast, human 
MSCs labeled with chitosan-coated superparamagnetic iron oxide did not exhibit any 
significant alterations in the surface marker expression or adipo /osteo /chondrogenic 
differentiation potential when compared to unlabeled control cells (Reddy et al., 2010).  
These studies show that careful selection of the MR contrast agent and modification protocol 
are required to retain full functionality of the cells after modification. Extensive in vitro and 
in vivo analyses of nanoparticle-loaded cells have to be conducted to ensure safety and 
effectiveness of the cell based diagnostic tool. As mammalian cells are well adapted to 
regulation of iron homeostasis, the use of ferumoxides appears clinically safe. So far, the 
iron oxide-based contrast agents Feridex and Resovist have been approved by the FDA. 
Despite technical challenges that still have to be addressed, the studies show that MSCs can 
be successfully loaded with the MR contrast agents and tracked via MRI. Besides MRI, other 
non-optical cell tracking methods are available, like positron emission tomography (PET) 
and single photon emission computed tomography (SPECT). An overview of stem cell 
tracking methods addressing their pros and cons can be found in reviews by Reagan and 
Kaplan (Reagan & Kaplan, 2011) and Srinivas et al. (Srinivas et al., 2010).  
Clinical studies tracking radiolabeled or SPIO labeled cells have been conducted with 
different cell types, including dendritic cells, neural stem cells, hematopoietic stem cells, and 
cadaveric islet cells (Bulte, 2009; Srinivas et al., 2010). With increasing clinical use of MSCs, 
the in vivo tracking of MSCs has become useful because it can help to evaluate and optimize 
MSC therapies. One phase I/II clinical study conducted in Jerusalem, Israel involved the 
administration of autologous Feridex-labeled MSCs in patients with multiple sclerosis and 
amyotrophic lateral sclerosis in an effort to prevent further neurodegeneration (Karussis et 
al., 2010). The Feridex-tag was added to allow cell tracking via MRI and evaluate migration 
of the transplanted cells. Intrathecal and intravenous administration were combined to 
maximize the potential therapeutic benefit by accessing the central nervous system through 
the cerebrospinal fluid and the systemic circulation. Of the 34 patients enrolled, nine 
patients received SMIO labeled (Feridex) MSCs. MRIs of the brain and whole spine 
performed at different time points after MSC injection indicated possible dissemination of 
the MSCs from the lumbar site of inoculation to the occipital horns, meninges, spinal roots, 
and spinal cord parenchyma. The results, however, need to be interpreted with caution, as 
the number of patients in the study is small and it is not ruled out that macrophages 
phagocytized the iron oxide magnetic resonance contrast agent and migrated to the 
inflammatory lesions. 
The ability of MSCs to migrate to sites of tumorigenesis might also allow for the 
development of labeled MSCs as a clinical tool for cancer detection. In support of this idea, 
Loebinger et al. showed that intravenously injected iron-labeled MSCs could be tracked in 
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vivo to multiple lung metastases using MRI (Loebinger et al., 2009b). Human MSCs were 
labeled with starch-coated FluidMAG iron nanoparticles and injected via the lateral tail vein 
into mice with metastatic lung tumors. MRI and immunohistological staining confirmed the 
localization of SPIO-loaded MSCs to lung metastases one hour after injection. Preceding 
experiments with mice carrying subcutaneous MDA-MB-231 tumors showed that as few as 
1,000 Feridex-labeled MSCs could be visualized in tumors using MRI (Loebinger et al., 
2009b). The ability to track MSCs homing to primary tumors and metastases using a 
noninvasive scanning method could be of great benefit for future diagnostic applications. 
4.2.2 Nanoparticle-loaded cells as therapeutic tool 
Besides diagnostic applications, nanoparticle-carrying cells are also interesting for 
therapeutic use. High Z-elements like gold can be utilized for radiotherapy enhancement 
(Butterworth et al., 2010; Chang et al., 2008; Chithrani et al., 2010; Hainfeld et al., 2004, 2008; 
Herold et al., 2000; Kong et al., 2008; Liu et al., 2010; Rahman et al., 2009; Rose et al., 1999), 
photothermal ablation of cancer cells by heating with near-infrared lasers (Atkinson et al., 
2010; Chen et al., 2010b; Cherukuri et al., 2010; Diagaradjane et al., 2008; Gobin et al., 2010; 
Kennedy et al., 2011), and thermal destruction of cancer cells by radiofrequency field-
induced heating (Gannon et al., 2008). Radiotherapy is one of the most commonly used 
methods in cancer therapy. Gold nanoparticles were shown to increase radiotherapy 
efficiency when accumulated in tumors due to their high absorption of X-rays (Hainfeld et 
al., 2008). However, injections of gold did not result in the delivery of gold nanoparticles to 
the tumor sites only. Although some nanoparticles were transported to the tumor via the 
EPR effect, others were detected in the blood, liver, spleen, and muscle, before renal 
clearance (Hainfeld et al., 2006). MSCs have been shown to home to sites of tumorigenesis 
and represent a potential vehicle for the targeted delivery of radiotherapy enhancers to 
tumor sites. Delivering a curative dose of radiation to tumor tissues, while sparing normal 
tissues, would help to reduce side effects of radiotherapy treatment and increase 
radiotherapy efficiency. 
First steps towards the development of cells carrying nanoparticles for radiotherapy 
enhancement have been made. Radiation enhancement was quantified in HELA cells by 
irradiating the cells with 220 kVp X-rays in the absence and presence of different sized 
internalized gold nanoparticles. Radiosensitization was dependent on the number of gold 
nanoparticles internalized in the cells, with gold nanoparticles of 50 nm diameter showing 
the highest radiosensitization enhancement factor (1.43 at 220 kVp) among gold 
nanoparticles ranging from 14 to 74 nm diameter. Radiation sensitization in HELA cells 
carrying 50 nm gold nanoparticles also depended on the energy of the radiation source 
(Chithrani et al., 2010).  
The enhancement of radiation effects by gold nanoparticles was also studied in bovine aortic 
endothelial (BAEC) cells (Rahman et al., 2009). Tumor growth and survival are critically 
linked to the proliferation of endothelial cells comprising the tumor blood vessel network 
(Sieman, 2006). Targeting the blood vessel network of a tumor with radiation aims to impair 
the nutritional support system of the tumor. Rahman et al. exposed BAEC cells carrying 1.9 
nm gold nanoparticles to kilovoltage X-ray radiation therapy and megavoltage electron 
radiation therapy. Dose enhancement in cells irradiated with superficial X-ray reached a 
dose enhancement factor of 24.6 with X-ray beams of 80 kVp and correlated with the 
concentration of internalized gold nanoparticles. Dose enhancement in cells irradiated with 
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electron beams reached a factor of 4.1. The study showed that gold nanoparticles can be 
used to enhance the effect of radiation doses from kilovoltage X-ray radiation therapy and 
megavoltage electron radiation therapy beams. As lower radiation doses destroy the same 
fraction of cells when gold nanoparticles are present as do larger radiation doses without 
radiosensitizers, the use of gold nanoparticles in radiotherapy might help to reduce 
radiation doses in the future (Rahman et al., 2009).  
4.3 Outlook on MSCs as targeted delivery tools 
Safety and ready availability of MSCs, together with their ability to home to sites of injury 
and tumorigenesis, and their low immunogenicity profile, makes them an attractive delivery 
vehicle for diagnostic and therapeutic purposes. Still, there are hurdles to be overcome 
before drug-loaded MSCs will be ready for clinical use. One of the challenges to be mastered 
is the effective loading of the vehicle cell with the therapeutic. MSCs must be loaded with 
drugs or modified to produce high enough concentrations of agent to reach therapeutic 
effectiveness without compromising cell viability and properties necessary for effective drug 
delivery (e.g. homing or migration potential). Several animal models have shown that 
therapeutically effective, modified MSCs can be generated (as discussed in section 4.1), and 
clinical trials will show whether those results can be translated into human use. Another 
necessity is the development of effective drug release mechanisms. Such mechanisms to 
initiate the release of the therapeutic from the MSCs to gain access to or enter the target cell 
remain to be found.  
Furthermore, for access to target sites, biological barriers, like the blood-brain barrier 
(Gabathuler, 2010; Patel et al., 2009), have to be crossed for the cells to be able to reach their 
target, which makes the route of administration another important factor to consider. In one 
study following intravenous injection of MSCs into rats after resuscitation from cardiac 
arrest, MSCs were detected in the brain. The number of detected cells was low, however 
neurologic recovery of the animals appeared to improve (Wang et al., 2008). Future studies 
have to demonstrate whether the number of MSCs crossing the blood-brain barrier is 
sufficient for therapeutically effective drug delivery. Alternatively, other routes of drug 
delivery could be chosen. Intranasally administered MSCs were shown to bypass the blood-
brain barrier by migrating from the nasal mucosa through the cribriform plate along the 
olfactory neural pathway into the brain and cerebrospinal fluid (Danielyan et al., 2009). Also 
local injections of drug-loaded MSCs might be considered to gain access to diseased tissue 
that is difficult to target. In this case, MSCs would be responsible for the “micro-targeting” 
of the drug very specifically within the target area.  
In addition to biological complications, there will also be technical hurdles in the 
development of drug-carrying MSCs. The successful transfer of MSC modification processes 
at the research scale to manufacturing levels could be challenging. Large-scale production of 
drug-loaded MSCs, whether it involves genetic modifications, culture-induced modification 
of cells, or loading of cells with nanoparticles, can be very expensive and time-consuming. 
Results from small-scale experiments cannot always easily be translated into large-scale 
production without significant additional efforts. Overall, MSCs are a very promising drug 
delivery tool. However, this new technology will only support widespread clinical use if 
effective drug loading and successful drug release at the site of interest can be ensured, and 
robust manufacturing processes are developed.  
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